ARTICLE | Emerging Company Profile

Orbital: an RNA toolbox for vaccines and protein replacement therapies

Arch-backed newco unites RNA pioneer Maraganore with technology from Stanford and sister company Beam Therapeutics

September 21, 2022 8:42 PM UTC

With linear RNA manufacturing and lipid nanoparticle technology from Beam, circular RNA and virus-like particle technology from Stanford, and founders including former Alnylam CEO John Maraganore, Stanford’s Howard Chang and Penn’s Drew Weissman, Orbital aims to build a toolbox of RNA technologies for vaccines and protein replacement applications.

Orbital Therapeutics Inc. launched on Sept. 7, with Beam Therapeutics Inc. (NASDAQ:BEAM) President and CSO Giuseppe Ciaramella as its CEO, Maraganore as chairman and a round of funding led by Arch Venture Partners. ...